|
Nitrite in Amines
|
|
15
|
949
|
May 21, 2026
|
|
N-Nitroso Perindopril Limit as NMI or 1500ng/day
|
|
3
|
246
|
May 21, 2026
|
|
Development and Validation of a Trace-Level LC–MS/MS Method for the Determination of N-Nitroso Clozapine in Clozapine Drug Substance -Pub
|
|
0
|
98
|
May 20, 2026
|
|
Strategies for Mitigating In-Source Fragmentation in NDSRI Analysis using LC-MS
|
|
4
|
2886
|
May 20, 2026
|
|
UHPLC-MS/MS Single Run Quantification Method for Simultaneous Determination of Triazolopyrazine and N-Nitroso-Triazolopyrazine in Sitagliptin; Risk Assessment, Scavenger-Based Mitigation, and Stress Stability Study -Pub
|
|
0
|
91
|
May 20, 2026
|
|
Liquid Chromatography–High-Resolution Mass Spectrometric Determination of Nitrite Ion Concentration in the Natural Water Resources -Pub
|
|
0
|
76
|
May 20, 2026
|
|
Simultaneous Determination of Duloxetine and N-Nitroso-Duloxetine in Reactor Cleaning Solvent Samples by LC–HRMS: Formation, Quantitation, and Green -Pub
|
|
0
|
121
|
May 20, 2026
|
|
N Nitroso Tadalfil
|
|
14
|
1110
|
May 20, 2026
|
|
🇰🇷 MFDS Guideline: Compilation of Analysis Methods on the Determination of Impurities in Pharmaceuticals, May-2026
|
|
2
|
285
|
May 19, 2026
|
|
Nitrosamine Workshop, Hyderabad, August 19 & 20
|
|
2
|
232
|
May 19, 2026
|
|
Source of N-nitroso-n-methylaniline (NMPA)
|
|
7
|
321
|
May 19, 2026
|
|
Regulatory Rationale for Restricting LTL Application to Nitrosamines
|
|
4
|
450
|
May 19, 2026
|
|
Analytical challenge for determination of instable standard of other N-nitroso structure
|
|
13
|
1131
|
May 18, 2026
|
|
Science-led approaches to nitrosamine qualification and safety assessment-webinar
|
|
1
|
215
|
May 15, 2026
|
|
N-Nitroso Metamizole Impurity C
|
|
4
|
387
|
May 13, 2026
|
|
N-Nitroso Mefanaminc Acid
|
|
1
|
147
|
May 12, 2026
|
|
Development of an Efficient and Scalable Process for Preparing Timolol N-Nitrosamine Impurities B, C, E, H, I, J, and Their ADMET Evaluation -Pub
|
|
2
|
181
|
May 8, 2026
|
|
Diluent Selection for Nitrosamine Impurities
|
|
7
|
344
|
May 8, 2026
|
|
FDA-CDER and HESI | Nitrosamine Ames Data Review and Method Development Workshop
|
|
2
|
401
|
May 6, 2026
|
|
Generic Drugs Forum (GDF) 2026
|
|
17
|
863
|
May 5, 2026
|
|
Benchmark Dose (BMD) Modeling for Risk Assessment webinar
|
|
1
|
311
|
May 4, 2026
|
|
Adjusting the Preincubation Conditions to Enhance the Ames Test for Detecting the Mutagenicity of N‐Nitrosamines-Pub
|
|
2
|
171
|
May 1, 2026
|
|
Hunt for NDSRIs: Unveiling Hidden Threats with the Novel 15N-Enriched NAP Test-Pub
|
|
3
|
500
|
April 30, 2026
|
|
Early life exposure to N-nitrosamine drives genotoxicity, mutagenesis, and tumorigenesis in DNA repair-deficient mice -Pub
|
|
5
|
460
|
April 30, 2026
|
|
N-Nitroso dially amine estimation by LCMS
|
|
2
|
92
|
April 29, 2026
|
|
N-NO formation in 2-mercaptobenzothiazole
|
|
2
|
132
|
April 29, 2026
|
|
Something in the air−Unveiling the role of atmospheric nitrogen oxides in nitrosamine formation from amine-containing APIs: Mechanistic insights and risk assessment-Pub
|
|
2
|
438
|
April 28, 2026
|
|
Nitrosamine limit in the specification based on intermediate and accelerated stability condition results
|
|
4
|
229
|
April 28, 2026
|
|
How to overcome blank interference at NDBA
|
|
4
|
196
|
April 27, 2026
|
|
🇯🇵 Current Nitrosamine Landscape in Japan?
|
|
186
|
17728
|
April 26, 2026
|